Calyxo, Inc.

About Calyxo, Inc.

Calyxo is a company focused on revolutionizing kidney stone care through innovative medical technologies and procedures aimed at improving patient outcomes.

Products & Services

CVAC System:A revolutionary device for kidney stone treatment with multiple capabilities including ureteroscopy, laser lithotripsy, microjet irrigation, dynamic aspiration, and stone collection.

SURE Procedure:A minimally invasive kidney stone treatment (Steerable Ureteroscopic Renal Evacuation) that uses laser lithotripsy, irrigation, and vacuum aspiration for complete stone clearance, performed exclusively with the CVAC System.

Specialties

Kidney Stone Treatment Ureteroscopy Laser Lithotripsy Minimally Invasive Procedures

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D T: - FT: Series D	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2023-12-12 FD: 2023-12-12	3 investors

Series D Latest

2023-12-12

$50.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Joe Catanese III

President and Chief Executive Officer

J

Jee Shin

Founder and Chief Business Officer

D

Doug Hughes

Chief Financial Officer

C

Chris Buchko

General Counsel

L

Lisa Campbell

Vice President, People

R

Ryan Connolly

Senior Vice President, Research and Development

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Calyxo, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised